Literature DB >> 29173362

Propofol Potentiates Sevoflurane-Induced Inhibition of Nuclear Factor--κB-Mediated Inflammatory Responses and Regulation of Mitogen-Activated Protein Kinases Pathways via Toll-like Receptor 4 Signaling in Lipopolysaccharide-Induced Acute Lung Injury in Mice.

Wei Liu1, Honghua Zhu1, Hao Fang2.   

Abstract

BACKGROUND: Toll-like receptor 4 (TLR4)-induced initiation of mitogen-activated protein kinases and the nuclear factor-kappa B signaling cascade is reportedly involved in inflammatory responses during lung injury. Studies have found that volatile anesthetics, such as isoflurane and sevoflurane, inhibit inflammation. This investigation explored the protective effects of propofol and whether propofol potentiates the protective effects of sevoflurane against lipopolysaccharide (LPS)-induced acute lung injury.
MATERIALS AND METHODS: Male BALB/c mice were treated with LPS (10μg/mouse; intranasal instillation) to induce acute lung injury. Mice were exposed to sevoflurane (3%; 6 hours) alone or combined with propofol (10 or 20mg/kg body weight; subcutaneously) followed by sevoflurane for 1 hour before the LPS challenge.
RESULTS: Sevoflurane with or without propofol attenuated pulmonary edema, restored altered lung architecture and reduced influx of inflammatory cells into bronchoalveolar lavage fluid after the LPS challenge. LPS-mediated overproduction of the proinflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin-6 as well as nitric oxide, were reduced. Sevoflurane either alone or with propofol downregulated TLR4 and TLR4-mediated mitogen-activated protein kinase and nuclear factor-kappa B signaling.
CONCLUSIONS: Combined exposure to propofol and sevoflurane was more effective than sevoflurane administered alone, suggesting the positive effects of propofol on sevoflurane-mediated anti-inflammatory effects.
Copyright © 2017 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute lung injury; Inflammation; Mitogen-activated protein kinases signaling; Propofol; Toll-like receptor 4

Mesh:

Substances:

Year:  2017        PMID: 29173362     DOI: 10.1016/j.amjms.2017.06.012

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

1.  Re: Examining the contribution of surrounding intact skin during cutaneous healing.

Authors:  Makram E Aljghami; Saied Amini-Nik
Journal:  J Anat       Date:  2019-11-24       Impact factor: 2.610

2.  'Examining the contribution of surrounding intact skin during cutaneous healing' by Aljghami M et al. Journal of Anatomy (2019) 234: 523-531.

Authors:  Wang ZhengHao; Li KaiNan
Journal:  J Anat       Date:  2019-10-28       Impact factor: 2.610

3.  Propofol Regulates the TLR4/NF-κB Pathway Through miRNA-155 to Protect Colorectal Cancer Intestinal Barrier.

Authors:  Yuhua Gao; Tao Han; Cailing Han; Hua Sun; Xiaoxia Yang; Dongmei Zhang; Xinli Ni
Journal:  Inflammation       Date:  2021-06-03       Impact factor: 4.092

4.  Anti-inflammatory effects of Lefty-1 in renal tubulointerstitial inflammation via regulation of the NF-κB pathway.

Authors:  Lijun Zhang; Changgeng Xu; Wei Hu; Pin Wu; Cong Qin; Jie Zhang
Journal:  Int J Mol Med       Date:  2017-12-18       Impact factor: 4.101

5.  The effect of repetitive exposure to intravenous anesthetic agents on the immunity in mice.

Authors:  Hyun Jun Park; Liyun Piao; Eun-Hye Seo; Seung Hyun Lee; Seong-Hyop Kim
Journal:  Int J Med Sci       Date:  2020-02-04       Impact factor: 3.738

Review 6.  Research Progress on the Pharmacological Action of Schisantherin A.

Authors:  Zehao Xiao; Wen Xiao; Guilin Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-12       Impact factor: 2.629

7.  Effects of sevoflurane and propofol anesthesia on intraoperative endothelial cell function in patients undergoing laparoscopic cholecystectomy.

Authors:  Yu Fan; Hao Wang; Qi Ma
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.